Want to see IN:NOVARTIND full AI Analyst Report?

Novartis India Limited (NOVARTIND) Price & Analysis

― Followers

NOVARTIND Stock Chart & Stats

₹1834.75

₹148.05(8.78%)

Oct 23, 2026

―

Day’s Range― - ―

52-Week Range₹750.00 - ₹2,588.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)4.96K

Market Cap

₹45.30B

Enterprise Value₹17.40B

Total Cash (Recent Filing)₹6.68B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)46.3

Beta-0.09

Next Earnings

Nov 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.36%

Share Statistics

EPS (TTM)39.61

Shares Outstanding24,690,796

10 Day Avg. Volume3,196

30 Day Avg. Volume4,964

Financial Highlights & Ratios

PEG Ratio-3.36

Price to Book (P/B)2.93

Price to Sales (P/S)6.76

P/FCF Ratio28.41

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low Financial LeverageA near debt-free balance sheet reduces interest burden and refinancing exposure, giving Novartis India greater resilience if operating conditions weaken. The substantial equity base also preserves flexibility to support commercialization, absorb volatility, and sustain operations without relying heavily on external financing.

Strong Recent ProfitabilitySustained mid-20% net margins across several recent years indicate that the branded-medicine commercialization model is currently producing attractive earnings from its revenue base. Strong profitability can support reinvestment, strengthen cash generation, and provide a durable buffer against moderate business fluctuations.

Recent Free Cash Flow StrengthRecent free cash flow that broadly tracks accounting profits provides evidence that earnings are being converted into usable funds. This supports the company’s ability to finance ongoing commercial activities, maintain financial independence, and return capital while retaining capacity to manage its business.

Bears Say

Uneven Revenue GrowthThe uneven revenue path shows that recent growth has not been consistently compounded across the period. Declines followed by rebounds can make planning and resource allocation less predictable, while the business may need continued execution to convert the latest improvement into a stable longer-term growth trajectory.

Volatile Cash ConversionAlthough cash generation has been solid lately, the history of negative operating cash flow and sharp changes in free cash flow growth indicates that conversion is not consistently stable. Such variability can complicate funding plans and make internally generated cash less dependable during weaker operating periods.

Earnings Growth Remains InconsistentThe negative EPS growth figure and prior loss indicate that improved recent profitability has not eliminated earnings volatility. An inconsistent earnings base can limit confidence in near-term profit compounding and leaves results more sensitive to changes in revenue performance, product mix, or operating conditions.

NOVARTIND FAQ

What was Novartis India Limited’s price range in the past 12 months?

Novartis India Limited lowest stock price was ₹750.00 and its highest was ₹2588.00 in the past 12 months.

What is Novartis India Limited’s market cap?

Novartis India Limited’s market cap is ₹45.30B.

When is Novartis India Limited’s upcoming earnings report date?

Novartis India Limited’s upcoming earnings report date is Nov 03, 2026 which is in 8 days.

How were Novartis India Limited’s earnings last quarter?

Novartis India Limited released its earnings results on Jul 23, 2026. The company reported ₹13.045 earnings per share for the quarter.

Is Novartis India Limited overvalued?

According to Wall Street analysts Novartis India Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis India Limited pay dividends?

Novartis India Limited pays a Annually dividend of ₹25 which represents an annual dividend yield of 1.36%. See more information on Novartis India Limited dividends here

What is Novartis India Limited’s EPS estimate?

Novartis India Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novartis India Limited have?

Novartis India Limited has 24,690,796 shares outstanding.

What happened to Novartis India Limited’s price movement after its last earnings report?

Novartis India Limited reported an EPS of ₹13.045 in its last earnings report. Following the earnings report the stock price went down -1.772%.

Which hedge fund is a major shareholder of Novartis India Limited?

Currently, no hedge funds are holding shares in IN:NOVARTIND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novartis India Limited

Novartis India Limited, an Indian healthcare enterprise, provides a diverse range of pharmaceutical solutions. Its offerings include branded medications for conditions related to bone and pain management, calcium supplementation, women's health (gynecology), and neurological disorders. Furthermore, the company supplies generic drugs specifically for gynecological issues, anti-tuberculosis treatments, and anti-infective applications. Notable branded products within its portfolio comprise Tegrital and Exelon for central nervous system disorders, Voveran for pain and inflammation relief, and specialized transplantation/immunology drugs like Simulect, Certican, Myfortic, and Sandimmun Neoral. Established in 1947 and headquartered in Mumbai, India, Novartis India Limited operates as a subsidiary of Novartis AG.